Cellectis To Present Pre-Clinical Data On Multi-Armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer At The Society For Immunotherapy Of Cancer 38th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Cellectis, a clinical-stage biotechnology company, announced that it will present pre-clinical data on MUC1-CAR T-cells for targeting solid tumors at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data is expected to overcome key challenges of targeting solid tumors. The meeting will take place on November 1-5, 2023.
September 27, 2023 | 8:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellectis is set to present pre-clinical data on MUC1-CAR T-cells, which could potentially overcome key challenges in targeting solid tumors. This could be a significant development for the company.
The presentation of pre-clinical data on MUC1-CAR T-cells by Cellectis could potentially lead to a breakthrough in the treatment of solid tumors. This could significantly boost the company's reputation and potentially its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100